On November 30, 2021, Astellas Pharma launched its antibody drug conjugate (ADC) Padcev (enfortumab vedotin) in Japan to treat patients with urothelial cancer, the most common form of bladder cancer type.
Padcev antibody conjugate drug is jointly developed by Astellas and Seagen Inc. The price of the drug is 99,609 yen (5597 yuan or 879 US dollars) per 30 mg vial.
Padcev (enfortumab vedotin) received fast-track approval in the United States in December 2019 (with formal approval in July 2021) and is already marketed under the product name PADCEV®.
In the United States, the price of Padcev 30mg is US$3,713, which is about 4.2 times the price in Japan.
Leave a reply